The downregulation of MFN2 in PAH as well as lung cancer, in part, appears to be tied to increased proteasomal degradation, which is triggered by PINK1-induced serine-442 MFN2 phosphorylation (Dasgupta et al., 2021). Here, MFN2 is linked to pulmonary arterial hypertension.